
# TGFbeta1-IN-2

## PRODUCT OVERVIEW

| | |
|---|---|
| **Product Name** | TGFbeta1-IN-2, Biochemical |
| **Full Product Name** | TGFbeta1-IN-2 |
| **Product Gene Name** | TGFbeta1-IN-2 biochemical |
| **Purity/Purification** | 99.2% |
| **Preparation and Storage** | Powder: -20 degree C for 3 years \| In solvent: -80 degree C for 1 year |
| **Molecular Weight** | 458.57 |
| **SMILES** | C(=NNC(=O)C1=CC=C(OCCCCCCN2CCCCC2)C=C1)C=3SC(N(=O)=O)=CC3 |
| **Formula** | C23H30N4O4S |
| **Solubility** | (< 1 mg/ml refers to the product slightly soluble or insoluble) |
| **CAS Number** | 2700263-58-5 |
| **In_vitro** | TGFbeta1-IN-2 (compound 52) administered orally at a dosage of 30-60 mg/kg once daily for 22 days has been shown to enhance pulmonary function and decelerate the progression of Idiopathic Pulmonary Fibrosis (IPF) in mice. Additionally, this compound can potentially reverse established pulmonary fibrosis in a treatment model [1]. In rats, the pharmacokinetic profile of TGFbeta1-IN-2 includes a maximum plasma concentration (C max) of 470.58+/-60.67 ng/mL following intravenous administration at 2 mg/kg and 351.01+/-85.44 ng/mL post oral administration at 20 mg/kg. The time to reach C max (T max) was 0.08 hours for intravenous and 2.17 hours for oral administration. The area under the curve (AUC 0-infinity) was 370.81+/-76.46 h·ng/mL intravenously and 1503.71+/-319.62 h·ng/mL orally. The clearance rate (CL) was 5565.86+/-1257.13 mL/h/kg intravenously. The half-life (T 1/2) of TGFbeta1-IN-2 was 0.93+/-0.43 hours intravenously and 1.23+/-0.15 hours orally, with an oral bioavailability (F) of 42.08+/-8.93% [1]. |
| **Related Product Information for TGFbeta1-IN-2 biochemical** | TGFbeta1-IN-2, a derivative of diarylacylhydrazones, effectively inhibits fibroblast activation and proliferation and holds potential for idiopathic pulmonary fibrosis (IPF) research. |
| **Other Notes** | Small volumes of TGFbeta1-IN-2 biochemical vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply. |
| **Searchable Terms for TGFbeta1-IN-2 purchase** | MBS5816927 is a biochemical targeting TGFbeta1-IN-2. |



**Structure of TGFbeta1-IN-2 biochemical**

**For Research Use Only.** Not for use in diagnostic or therapeutic procedures.